Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 2NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Pancreatic Neoplasms 153Carcinoma, Non-Small-Cell Lung 94Neoplasms 57Breast Neoplasms 50Urinary Bladder Neoplasms 47Neoplasm Metastasis 43Lung Neoplasms 41Ovarian Neoplasms 36Cholangiocarcinoma 31Lymphoma 20Sarcoma 19Gallbladder Neoplasms 19Fallopian Tube Neoplasms 19Lymphoma, Large B-Cell, Diffuse 18Biliary Tract Neoplasms 18Recurrence 15Lymphoma, Non-Hodgkin 15Adenocarcinoma 14Hodgkin Disease 13Carcinoma, Transitional Cell 13Bile Duct Neoplasms 13Carcinoma 12Colorectal Neoplasms 10Head and Neck Neoplasms 8Carcinoma, Renal Cell 8Urethral Neoplasms 7Parkinson Disease 4, Autosomal Dominant Lewy Body 7Carcinoma, Ovarian Epithelial 7Adenocarcinoma of Lung 7Uterine Cervical Neoplasms 6

Interventions

Gemcitabine 4Fluorouracil 4dehydroftorafur 3Taxes 3Oxaliplatin 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3Radiotherapy 2Leucovorin 2Irinotecan 2tocilizumab 1selicrelumab 1niraparib 1indusatumab 1cobimetinib 1atezolizumab 1X-Rays 1Tiragolumab 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiation 1Pancreatectomy 1PEGPH20 1Nivolumab 1Losartan 1Ipilimumab 1Folfox protocol 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Pancreatic Adenocarcinoma × Gemcitabine × Clear all
NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Active not recruiting
42 enrolled 13 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Hoffmann-La Roche

Phase 1/2 Completed
341 enrolled 28 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT02427841 2023-09-06

Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

OHSU Knight Cancer Institute

Phase 2 Completed
20 enrolled 17 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT02562716 2022-10-19

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

SWOG Cancer Research Network

Phase 2 Completed
147 enrolled 16 charts
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡